Abstract Library

#2906 Change of Lactate Transporter (MCT4) Expression in Pancreatic Microadenomas and Stages of Pancreatic Neuroendocrine Tumors

Introduction: Metabolic changes are observed in early and late stages of Pancreatic Neuroendocrine Tumors (PanNET) in mouse models. In human PanNET, RNA-expression analysis showed changes in glucose metabolism in more aggressive PanNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Bräutigam K

Authors: Straub J, Bräutigam K, Di Domenico A, Galván J, Maire R,

Keywords: metabolism, microadenoma, immunohistochemistry, pancreas, tumor, mct4, relapse,

#2826 NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC)

Introduction: The prognosis for pts with PD-EP-NEC is poor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: McNamara M

Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,

Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,

#2739 Epigenetic Landscape of Pancreatic Neuro-Endocrine Tumors Reveals Distinct Cells of Origin and Means of Tumor Progression

Introduction: Pancreatic Neuroendocrine Tumors (PanNETs) arise from cells of the Islets of Langerhans. The majority of PanNETs are non-functional and their cell of origin cannot be defined analysing specific hormone production. Cell of origin assessment has proven importance to identify risk factors, prevent tumour development, and tailor treatment in many malignancies. Recent data on super-enhancer signatures has suggested a potential origin of PanNET from α- or β-cells. We and others have shown that distinct epigenetic profiles assessed by DNA methylation (DNAme) characterize genomic and prognostic groups of PanNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Di Domenico A

Authors: Di Domenico A, Pipinikas C, Maire R, Bräutigam K, Vassella E,

Keywords: cell of origin, alpha, beta, methylation, expression, epigenetic, neuroendocrine, progression, PanNET, tumor,

#2128 Epigenetic Changes in DAXX and/or ATRX Negative Pancreatic Neuro-Endocrine Tumors

Introduction: The most commonly mutated genes in Pancreatic Neuroendocrine Tumors (PanNETs) are MEN1, DAXX and ATRX, which encode for proteins involved in epigenetic regulation. DAXX/ATRX mutated PanNETs are globally hypomethylated and behave clinically in a more aggressive way. Tumor pathways associated with these changes are still unclear. We hypothesize that DAXX/ATRX and MEN1 mutations mediate PanNET progression via epigenetic dysregulation.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Di Domenico A

Authors: Di Domenico A, Pipinikas C, Simillion C, Wiedmer T, Maire R,

Keywords: methylation, expression, miRNA, epigenetic, PanNETs, neuroendocrine, tumors, MEN1, DAXX, ATRX, progression,

#1872 Whole-Exome Sequencing (WES) of Samples from Patients (pts) Classified as Exceptional Responders (ER) vs Poor Responders (PO) to Targeted Therapies in Pancreatic Neuroendocrine Tumours (pNETs).

Introduction: Sunitinib (SU) and everolimus (EVE) changed the treatment landscape for patients with well-differentiated pNETs. However, no predictive biomarkers have been established for these drug

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Barriuso J, Lamarca A, McNamara M, Manoharan P, Moghadam S,

Keywords: pNETs, WES, everolimus, sunitinib,